An integrated valuation model for payer and investor
Background In order to optimize positioning and associated drug price for both payer and investor, it is for a company essential to forecast the potential market access attractiveness for the new drug for different indications at the early onset of the clinical development program. This analysis mus...
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Taylor & Francis Group
2022-12-01
|
| coleção: | Journal of Market Access & Health Policy |
| Assuntos: | |
| Acesso em linha: | https://www.tandfonline.com/doi/10.1080/20016689.2022.2080631 |